TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00323323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Samples
Description: Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
Study: NCT03696160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Integrase inhibitor used to treat HIV-1 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza
Description: Protease inhibitor used to treat HIV-1 infection
Study: NCT02275702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone IV
Description: It will be administered at the induction of the anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study: NCT04068025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigned Interventions
Description: Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life.
Study: NCT02195765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enamel matrix derivative
Description: Open flap debridement associated with enamel matrix derivative

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Open flap debridement
Study: NCT03779256

Intervention type: PROCEDURE
Intervention: 2D transvaginal ultrasound
Description: Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively.
Study: NCT04389775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.
Study: NCT02163239

Intervention type: DEVICE
Intervention: Cannula and Blunt Obturator
Description: The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
Study: NCT04529083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mr. MAPP
Description: Mixed reality device to provide virtual mirror therapy to patients with phantom pain
Study: NCT00783159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power Training
Description: Power training, Vitamin D substitution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Strength training, Vitamin D substitution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Vitamin D substitution, Lifestyle consultation
Study: NCT02913339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Risk Assessment
Description: Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Risk Assessment
Description: Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
Study: NCT04091620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Total Mesorectal Excision
Description: As above

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Total Mesorectal Excision
Description: As above
Study: NCT01434017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
Study: NCT02120742

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS message reminder
Description: SMS texts will be delivered to study participants over a 6-week period.
Study: NCT01434017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and droperidol
Description: Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and Ondansetron
Description: Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
Study: NCT00497614

Intervention type: DRUG
Group type: OTHER
Intervention: adalimumab
Study: NCT04099563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers
Study: NCT02965911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
Study: NCT03160638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg
Description: Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
Study: NCT03809728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic biopsy
Description: Per-endoscopic biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: samples of the oral cavity
Description: 7 samples of the oral cavity with a swab

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Samples of the resected specimen
Description: if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
Study: NCT02388269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore®-G
Description: The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore®-G
Description: The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
Study: NCT00603317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo
Description: Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
Description: Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
Study: NCT04182516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03305293
Description: All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
Study: NCT00823316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord blood-derived mesenchymal stem cells
Description: 1x1,000,000 hMSC/kg, IV after unrelated HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord blood-derived mesenchymal stem cells
Description: 5x1,000,000 hMSC/kg, IV after unrelated HSCT
Study: NCT00941746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG110
Description: Single, slow intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single, slow intravenous infusion that matches PG110 in appearance
Study: NCT04005846

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
Study: NCT03463057

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
Study: NCT02120742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS message reminder
Description: SMS texts will be delivered to study participants over a 6-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS message reminder
Description: SMS texts will be delivered to study participants over a 6-week period.
Study: NCT01626014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Educational Website
Description: Using the control website: Participants access a website with standard ovarian cancer informational handouts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prototype System
Description: An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
Study: NCT00217984

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Referral to smoking cessation clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended cognitive behavior therapy
Description: 16 sessions of cognitive behavior therapy over 6 months
Study: NCT04664543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free diet
Description: To follow the regular dietary habits with no restriction nor modification.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Three days low residue diet
Description: To follow the three days before colonoscopy a diet with low content in fiber or residues.
Study: NCT03632135

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ChemoID assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ChemoID assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
Study: NCT03674593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral valve chordae prosthesis
Description: The method consists of five stages:~1. Measure the required length of the chords~2. Forming loops~3. Fixation of the loop group to the papillary muscles~4. Fixation of chordal loops to the free edge of the valve~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve chordae translocation
Description: The method consists essentially of three stages:~1. Selection of the secondary chord.~2. Fixation of secondary chords to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse.
Study: NCT01970631

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
Study: NCT01321320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active muscle stimulation
Description: Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
Study: NCT02105922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Resistance Training
Description: Supervised Heavy Resistance Training three times weekly for 3 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Intensity Training
Description: Home-based Light Intensity Training three-five times weekly for 3 months.
Study: NCT03740022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL plasty
Description: standard ligamentoplasty by Kenneth Jones

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL + ALL plasty
Description: standard ligamentoplasty and anterolateral plasty